Inheart funding news – Medical Device Company Inheart Secures USD11Million in Funding

Read also - Insempra funding news – Biotech Startup Insempra Secures $20 Million in Series A Round Funding

The financing was led by Vesalius Biocapital IV and co-led by Elaia Partners with participation from NACO, Sagana,Sofia Angel Ventures, CWR Funds, and Webit Investment Network. In addition,inHEART received funds from a successful crowd equity campaign on Tudigo andfrom the UK impact fund Astorg Foundation.

Todor Jeliaskov, Chairman and CEO of inHEART said, “We welcome this strong international group of investors to our latest round of financing, This new round allows us to go further in addressing the needs of cardiac patients from early screening and disease detection through advanced therapeutic support. It’s exciting for us to be at the forefront of transforming the healthcare industry with the power of AI technology by improving the efficiency of care, quality of decision-making, and effectiveness and safety of medical interventions.”

SamanthaJ érusalmy, board member at inHEART and Partner at Elaia said, “We are enthusiastic to continue our support and co-lead this financing round for inHEART, inHEART’s AI-driven 3D cardiac mapping enables unprecedented precision in targeting and treating arrhythmias, setting new standards in the treatment of heart conditions.”

Jean-Christophe Renondin, Managing Partner at Vesalius Biocapital IV said, “At Vesalius Biocapital IV, we're dedicated to supporting advancements in medical technology that improve patient care. It's AI-driven solutions exemplify the future of cardiac care, offering personalized therapy options and predictive models that can enhance clinical outcomes and streamline treatment processes.We're excited to contribute to it's journey as they revolutionize cardiac care and address global healthcare needs with cutting-edge technology and innovation.”

About inHEART

inHEART is delivering the world’s first AI-driven, digital twin of the heart to advance the care of patients living with cardiac disease. They are committed to addressing the needs of the cardiac care continuum by providing personalized therapy in a predictive manner for screening and early detection of cardiac diseases.